C07K 2317/77
Internalization into the cell
C07K2317/77 (Internalization into the cell) appears on 1,960 US grants and 3,606 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,960
- Published applications
- 3,606
- Assignees
- 1,082
- Inventors
- 6,086
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 2 | 0 |
| 1991 | 0 | 0 |
| 1992 | 2 | 0 |
| 1993 | 7 | 0 |
| 1994 | 3 | 0 |
| 1995 | 8 | 0 |
| 1996 | 12 | 0 |
| 1997 | 16 | 0 |
| 1998 | 17 | 0 |
| 1999 | 20 | 0 |
| 2000 | 24 | 0 |
| 2001 | 17 | 9 |
| 2002 | 19 | 31 |
| 2003 | 17 | 58 |
| 2004 | 17 | 59 |
| 2005 | 11 | 66 |
| 2006 | 12 | 62 |
| 2007 | 23 | 65 |
| 2008 | 30 | 73 |
| 2009 | 52 | 132 |
| 2010 | 53 | 115 |
| 2011 | 48 | 110 |
| 2012 | 63 | 110 |
| 2013 | 72 | 121 |
| 2014 | 85 | 134 |
| 2015 | 97 | 143 |
| 2016 | 120 | 207 |
| 2017 | 113 | 182 |
| 2018 | 115 | 165 |
| 2019 | 108 | 177 |
| 2020 | 102 | 174 |
| 2021 | 101 | 180 |
| 2022 | 114 | 217 |
| 2023 | 101 | 228 |
| 2024 | 115 | 299 |
| 2025 | 148 | 285 |
| 2026 | 94 | 204 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Bifunctional molecules for lysosomal targeting and related compositions and methods6 Oct 2026US 12,753,239 B2The Board of Trustees of the Leland Stanford Junior University
- Muscle-targeting complexes and uses thereof22 Sep 2026US 12,742,007 B2Dyne Therapeutics, Inc.
- Monoclonal antibodies against CLDN18.2 and Fc-engineered versions thereof15 Sep 2026US 12,735,479 B2Shijiazhuang Yiling Pharmaceutical Co., Ltd.
- Epithelial cadherin-specific antibodies15 Sep 2026US 12,735,498 B2Kling Biotherapeutics B.V.
- Radiolabeled met binding proteins for immuno-pet imaging8 Oct 2026US 2026/0306682 A1Regeneron Pharmaceuticals, Inc.
- Multispecific antibodies targeting cd3 and cd228 Oct 2026US 2026/0308255 A1
- Ceacam1-targeting antibodies and uses thereof1 Oct 2026US 2026/0297187 A1Suzhou Neologics Bioscience Co., Ltd.
- Novel EGFR Binding Proteins1 Oct 2026US 2026/0297200 A1
- Anti-cmet antibody1 Oct 2026US 2026/0297202 A1Pierre Fabre Medicament
Most cited
By later US patents
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Expression of functional antibody fragments507US 5,648,237 AGenentech, Inc. · 1997
- Transgenic mice depleted in a mature lymphocytic cell-type491US 5,591,669 AGenPharm International, Inc. · 1997
- Optimized Fc variants463US 7,317,091 B2Xencor, Inc. · 2008
- Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells304US 5,789,554 AImmunomedics, Inc. · 1998